Abstract

In recent years, spectral computed tomography (CT) has shown excellent performance in the diagnosis of ground-glass nodules (GGNs) invasiveness; however, no research has combined spectral multimodal data and radiomics analysis for comprehensive analysis and exploration. Therefore, this study goes a step further on the basis of the previous research: to investigate the value of dual-layer spectral CT-based multimodal radiomics in accessing the invasiveness of lung adenocarcinoma manifesting as GGNs. In this study, 125 GGNs with pathologically confirmed preinvasive adenocarcinoma (PIA) and lung adenocarcinoma were divided into a training set (n=87) and a test set (n=38). Each lesion was automatically detected and segmented by the pre-trained neural networks, and 63 multimodal radiomic features were extracted. The least absolute shrinkage and selection operator (LASSO) was used to select target features, and a rad-score was constructed in the training set. Logistic regression analysis was conducted to establish a joint model which combined age, gender, and the rad-score. The diagnostic performance of the two models was compared by the receiver operating characteristic (ROC) curve and precision-recall curve. The difference between the two models was compared by the ROC analysis. The test set was used to evaluate the predictive performance and calibrate the model. Five radiomic features were selected. In the training and test sets, the area under the curve (AUC) of the radiomics model was 0.896 (95% CI: 0.830-0.962) and 0.881 (95% CI: 0.777-0.985) respectively, and the AUC of the joint model was 0.932 (95% CI: 0.882-0.982) and 0.887 (95% CI: 0.786-0.988) respectively. There was no significant difference in AUC between the radiomics model and joint model in the training and test sets (0.896 vs. 0.932, P=0.088; 0.881 vs. 0.887, P=0.480). Multimodal radiomics based on dual-layer spectral CT showed good predictive performance in differentiating the invasiveness of GGNs, which could assist in the decision of clinical treatment strategies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.